Olema Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Welcome, everyone. This is Josh Schimmer from the Evercore ISI biotech team, part of the 5th Annual HealthCONx Conference. Can't believe we're already on year five.
Very pleased to introduce from Olema Oncology, we have Sean Bohen, President and Chief Executive Officer. And we have spent so much time talking to Olema, trying to wrap our heads around the SERD space, the CERAN space for breast cancer. It is simple and tricky all at the same time for all sorts of interesting reasons. So I'm hoping that in our limited time that we have over 20 minutes, we can talk about some of the [movable] parts of the space and understand the relative positioning of 1250 and its path to market. So Sean, thank you for the time, welcome.
Questions & Answers
Why don't we start with 1250? And what's a CERAN compared to a SERD or a degrader -- because we're toggling back and forth talking about these, but I think important to just set the stage first with what differentiates different
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
